Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marinomed Biotechnologie has signed a licensing agreement with Boehringer Ingelheim to further extend marketing of Marinomed’s anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South America, parts of Asia and Australia.
Subscribe to our email newsletter
Marinomed said that the nasal spray is based on its anti-viral respiratory technology platform mavirex.
‘mavirex’ is Marinomed’s proprietary anti-viral respiratory technology platform to develop therapies that target more than 200 different respiratory virus strains and Marinomed is investigating the technology for use in a range of other products.
As per the contract Marinomed is expected to get an upfront payment in the million EUR range from Boehringer Ingelheim, in addition to payments upon the achievement of certain market entry milestones and royalties.
Further, Boehringer Ingelheim intends to market the anti-viral nasal spray under the cough and cold brand Mucosolvan.
Andreas Grassauer, co-founder and CEO of Marinomed, said: “Our anti-viral respiratory technology platform has already been validated in clinical trials with adults and children, demonstrating efficacy as an antiviral treatment in treating the cause of the common cold.”
David Wright, corporate senior vice president of consumer healthcare at Boehringer Ingelheim, said: “This licensing agreement is an excellent strategic fit with our ongoing development of new and innovative products designed to afford consumers a range of Over-the-Counter medicines to treat the common cold and related diseases, as well as their associated symptoms.”